Literature DB >> 8585764

Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.

R F Azad1, V Brown-Driver, R W Buckheit, K P Anderson.   

Abstract

ISIS 2922 is a phosphorothioate oligonucleotide with potent antiviral activity against human cytomegalovirus (HCMV) in cell culture assays. The ability of ISIS 2922 to inhibit replication of HCMV when used in combination with other antiviral agents approved for treatment of HCMV disease was investigated using a 96-well immunoassay. The antiviral activity of ISIS 2922 against HCMV was additive with that of ganciclovir (9-(1,3-dihydroxy-2-propoxymethylguanine); DHPG) or foscarnet (phosphonoformate). Compounds used clinically for the treatment of human immunodeficiency virus infection and likely to be co-administered with ISIS 2922 in the clinic were also evaluated for their ability to modulate the antiviral activity of ISIS 2922. 3'-Azido-3'-deoxythymidine (AZT) exhibited no antiviral activity against HCMV in the 96-well immunoassay, and did not significantly alter the antiviral activity of ISIS 2922. 2'-3'-Dideoxycytidine (ddC) was able to inhibit replication of HCMV at high doses, and this activity was additive with that of ISIS 2922. ISIS 2922 inhibited HIV replication in acute infection assays at relatively high concentrations as previously reported for non-complementary phosphorothioate oligonucleotides. When ISIS 2922 was used in combination with AZT in this assay, interactions were additive at most concentrations, although significant and reproducible synergy was observed at some concentration combinations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585764     DOI: 10.1016/0166-3542(95)00035-k

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.

Authors:  M Marschall; M Freitag; S Weiler; G Sorg; T Stamminger
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.

Authors:  K P Anderson; M C Fox; V Brown-Driver; M J Martin; R F Azad
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 3.  Fomivirsen.

Authors:  C M Perry; J A Balfour
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 4.  External guide sequence technology: a path to development of novel antimicrobial therapeutics.

Authors:  Carol Davies-Sala; Alfonso Soler-Bistué; Robert A Bonomo; Angeles Zorreguieta; Marcelo E Tolmasky
Journal:  Ann N Y Acad Sci       Date:  2015-04-09       Impact factor: 5.691

5.  Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNALys3 are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells.

Authors:  R El Dirani-Diab; L Sarih-Cottin; B Delord; B Dumon; S Moreau; J J Toulme; H Fleury; S Litvak
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 6.  Fomivirsen: clinical pharmacology and potential drug interactions.

Authors:  Richard S Geary; Scott P Henry; Lisa R Grillone
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.